Said Sebti
Said Sebti (, (first name () is an American cancer researcher who is Professor and Chairman of the Department of Drug Discovery at the H. Lee Moffitt Cancer Center & Research Institute in Tampa, Fl. Sebti is noted for his work to rehabilitate the 'failed' cancer drug Triciribine, now under development at the pharmaceutical company Prescient Therapeutics (ASX: PTX). Sebti is currently Chief Scientific Officer at Prescient Therapeutics. Provided by Wikipedia
Showing 1 - 4 results of 4 for search 'Said Sebti', query time: 0.03s
Refine Results
-
1
-
2
Comparison of different Lewis acids supported on natural phosphate as new catalysts for chemoselective dithioacetalization of carbonyl compounds under solvent-free conditions by Mohamed Zahouily, Abdessamad Mezdar, Abdelhakim Elmakssoudi, Ahmed Rayadh, Saïd Sebti, Hassan Bihi Lazrek
Published 2005-11-01
Article -
3
A Phase I Safety, Pharmacokinetic, and Pharmacodynamic Presurgical Trial of Vitamin E δ-tocotrienol in Patients with Pancreatic Ductal Neoplasia by Gregory M. Springett, Kazim Husain, Anthony Neuger, Barbara Centeno, Dung-Tsa Chen, Tai Z. Hutchinson, Richard M. Lush, Saïd Sebti, Mokenge P. Malafa
Published 2015-12-01
Article -
4
Protein Prenylation Constitutes an Endogenous Brake on Axonal Growth by Hai Li, Takaaki Kuwajima, Derek Oakley, Elena Nikulina, Jianwei Hou, Wan Seok Yang, Emily Rhodes Lowry, Nuno Jorge Lamas, Mackenzie Weygandt Amoroso, Gist F. Croft, Raghavendra Hosur, Hynek Wichterle, Said Sebti, Marie T. Filbin, Brent Stockwell, Christopher E. Henderson
Published 2016-07-01
Article